CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
nebulised liposomal amphotericin Bdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00263315
NCT00263315Phase 3Completed
CompareCT.gov

Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial.

Erasmus Medical Center·interventional·Posted Dec 8, 2005·Updated Aug 18, 2006

In Brief

A Phase 3 clinical trial evaluating nebulised liposomal amphotericin B for Aspergillosis. Completed, across 2 sites.

Detailed Summary

A Phase II/III randomized double-blind study comparing the safety and the efficacy of a weekly administration of 25 mg nebulized AmBisome with nebulized placebo solution to prevent invasive pulmonary aspergillosis in neutropenic hemato-oncologic patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspergillosis
CountriesNetherlands
CollaboratorsGilead Sciences, Nexstar Pharmaceuticals

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 8, 2005
Enrollment StartJan 1, 2000
Study CompletionMay 1, 2006
TodayJul 2, 2026
Posted 20.6 years ago

Interventions

nebulised liposomal amphotericin Bdrug